Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: A prospective 5-year study

Journal of Bone and Mineral Research

Volumn 25, Issue 4, 2010, Pages 866-872

  Cameron, Ian D ^a   Chen, Jian Sheng ^a   March, Lyn M ^a   Simpson, Judy M ^b   Cumming, Robert G ^a   Seibel, Markus J ^a   Sambrook, Philip N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aged care facility; Elderly; Hip fracture; Mortality; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AGE DISTRIBUTION; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HIP FRACTURE; HUMAN; IMMOBILIZATION; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; SEX RATIO;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COMMUNICABLE DISEASES; DIPHOSPHONATES; FEMALE; FRAIL ELDERLY; HIP FRACTURES; HUMANS; INSTITUTIONALIZATION; MALE; NURSING HOMES; OSTEOPOROSIS; PROSPECTIVE STUDIES;

EID: 77953448661     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.091029     Document Type: Article

References (23)

1. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513-521.
2. Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE. Survival experience of aged hip fracture patients. Am J Public Health. 1989;79:274-278. (Pubitemid 19077861)
3. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
4. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the reduction in mortality with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25:91-97.
5. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137:1001-1005. (Pubitemid 23191067)
6. Schroder HM, Erlandsen M. Age and sex as determinants of mortality after hip fracture: 3,895 patients followed for 2.5-18 5 years. J Orthop Trauma. 1993;7:525-531.
7. Hannan EL, Magaziner J, Wang JJ, et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA. 2001;285:2736-2742. (Pubitemid 32525370)
8. Sambrook PN, Chen JS, March LM, et al. Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab. 2004;89:1572-1576.
9. Zochling J, Sitoh YY, Lau TC, et al. Quantitative ultrasound of the calcaneus and falls risk in the institutionalized elderly: sex differences and relationship to vitamin D status. Osteoporos Int. 2002;13:882-887. (Pubitemid 35364789)
10. Holtzman J, Lurie N. Causes of increasing mortality in a nursing home population. J Am Geriatr Soc. 1996;44:258-264. (Pubitemid 26081091)
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
12. Chen JS, Cameron ID, Cumming RG, et al. Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res. 2006;21:324-331.
13. Empana JP, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc. 2004;52:685-690. (Pubitemid 38596484)
14. Lu-Yao GL, Baron JA, Barrett JA, Fisher ES. Treatment and survival among elderly Americans with hip fractures: a population-based study. Am J Public Health. 1994;84:1287-1291. (Pubitemid 24250699)
15. Luthje P, Kataja M, Nurmi I, Santavirta S, Avikainen V. Four-year survival after hip fractures-an analysis in two Finnish health care regions. Ann Chir Gynaecol. 1995;84:395-401. (Pubitemid 26061978)
16. Magaziner J, Zimmerman SI, Gruber-Baldini AL, Hebel JR, Fox KM. Proxy reporting in five areas of functional status. Comparison with self-reports and observations of performance. Am J Epidemiol. 1997;146:418-428. (Pubitemid 27377519)
17. Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health. 1991;105:443-446.
18. Rapp K, Becker C, Lamb SE, Icks A, Klenk J. Hip fractures in institutionalized elderly people: incidence rates and excess mortality. J Bone Miner Res. 2008;23:1825-1831.
19. Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: From the cardiovascular health study. J Am Geriatr Soc. 2006; 54:1885-1891. (Pubitemid 44915832)
20. Wehren LE, Hawkes WG, Orwig DL, Hebel JR, Zimmerman SI, Magaziner J. Gender differences in mortality after hip fracture: the role of infection. J Bone Miner Res. 2003;18:2231-2237. (Pubitemid 37463317)
21. Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009;58:31-38.
22. Carbone LD, Warrington KJ, Barrow KD, et al. Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol. 2006;146:371-380.
23. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:1809-1822. (Pubitemid 46698462)